If You Invested in Kenwin Shops Inc (KNWN)

Know Labs, Inc. (KNWN) is a public company whose shares trade under the stock symbol KNWN on the over-the-counter market. The company is described in its public communications as a pioneering leader in the development and application of radio frequency dielectric spectroscopy (RFDS) and related radio frequency spectroscopy technologies for non-invasive medical diagnostics and other fields of use.

According to Know Labs, its platform technology directs electromagnetic energy through a substance or material to capture a unique molecular signature. The company believes this patented and patent-pending technology can be integrated into a variety of wearable, mobile or bench-top form factors. Based on the company’s statements, this approach is intended to enable the identification and monitoring of analytes that previously required invasive and/or expensive and time-consuming lab-based tests.

Core technology and applications

Know Labs describes its RFDS-based platform as a foundational technology that can support multiple applications. In its disclosures, the company notes that one of its first expected applications is a product marketed as a non-invasive glucose monitor. This device is designed to provide users with accessible and affordable real-time information on blood glucose levels. The company states that this product will require clearance or approval from the U.S. Food and Drug Administration (FDA) prior to introduction to the market.

The company also indicates that it is pursuing additional applications for its technology through its Know Labs Technology Licensing (KTL) program. In its descriptions of KTL, Know Labs explains that some products developed through this licensing initiative may not require prior FDA approval, depending on their field of use and regulatory status. Beyond medical diagnostics, the company references potential use of its RFDS technology in areas such as industrial process control and other fields where capturing molecular signatures may be valuable.

Know Labs Technology Licensing (KTL)

Know Labs Technology Licensing (KTL) is presented as the dedicated licensing division of Know Labs, Inc. The company states that KTL is intended to facilitate the global adoption of its patented RFDS technology by corporations, universities, and research institutions. KTL focuses on structured intellectual property (IP) licensing, customization, and implementation support related to Know Labs’ RFDS sensor technology, products and services.

In its public materials, Know Labs notes that KTL is built on an extensive IP portfolio that includes hundreds of issued, pending and in-process patents, as well as a large number of codified trade secrets. The company highlights a patent-pending digital watermark technology called e-RFDS™ (also referred to as e-RFDS©), which is described as a way to authenticate RFDS digital signatures and support patent security, counterfeit protection, and authenticity validation for users of RFDS-based developments.

The company has outlined a multi-phase engagement model for KTL that includes licensee onboarding and assessment, data collection and customization, advanced data integration and AI modeling, optional wet lab support, and intellectual property and reporting support. This framework is intended to guide partners from initial engagement through full RFDS integration and related IP development.

Intellectual property focus

Know Labs emphasizes that protection of its inventions has been a central focus since its inception. In a recent update, the company reported a portfolio of hundreds of patents (issued, pending and in process) and over one thousand codified trade secrets. It also cited an independent third-party analysis indicating that, in certain categories of medical diagnostics and industrial process control, its patent portfolio ranks highly relative to other portfolios, based on that analysis. The company states that its patents and trade secrets are expected to grow over time as innovation continues.

Know Labs describes its intellectual property strategy as covering core elements of how its technology works and a wide range of potential applications across diverse industries and fields of use. The company also notes that its trade secrets, codified through a third-party trade secret platform, are considered a key component of its overall IP portfolio, particularly in the context of its licensing activities through KTL.

Trading status and listing history

Know Labs’ shares have traded under the symbol KNWN on the over-the-counter markets and previously traded on the NYSE American exchange under the symbol KNW. The company has disclosed that NYSE Regulation commenced delisting proceedings under Section 1003(f)(v) of the NYSE American Company Guide related to the company’s share price. During this process, the company’s stock was suspended from trading on NYSE American, and the symbol KNWN was assigned for quotation and trading in the over-the-counter market.

The company has reported that it filed an appeal of the NYSE American’s commencement of proceedings to delist and has taken actions such as a reverse stock split to address listing criteria. In subsequent communications, Know Labs announced that its common shares were approved to quote on the OTCQB Venture Market under the ticker symbol KNWN. The company notes that the OTCQB is recognized by the U.S. Securities and Exchange Commission as an established public market for entrepreneurial and development-stage companies, with eligibility requirements related to financial reporting, bid price, and company verification.

Business context and sector

Know Labs is classified in the Manufacturing sector, with an industry description of Electromedical and Electrotherapeutic Apparatus Manufacturing. In its public descriptions, the company positions itself as an emerging or pioneering leader in non-invasive medical diagnostic technology based on RFDS and related spectroscopy methods. It has also indicated that it is working to reduce fixed expenses and continues to focus on developing its diagnostic platform, with an initial emphasis on blood glucose monitoring.

The company has disclosed that its audited financial statements included an explanatory paragraph related to its ability to continue as a going concern, and that it plans to seek additional funding through equity and debt offerings. These disclosures are part of its regulatory reporting and are referenced in its public announcements.

Overview of KNWN stock

The KNWN stock represents an interest in Know Labs, Inc., a company focused on RFDS-based platform technology and intellectual property licensing. Investors and observers who follow KNWN are often interested in the company’s progress toward regulatory clearance for its non-invasive glucose monitoring product, the expansion and licensing of its IP portfolio through KTL, and developments related to its trading status on over-the-counter markets and any exchange listing appeals.

Because Know Labs emphasizes long-term technology and IP development, information about its patents, trade secrets, and licensing framework is central to understanding its business. At the same time, the company’s own disclosures highlight financial and listing risks, including going concern considerations and past delisting proceedings, which are relevant factors for those researching KNWN as a speculative, development-stage stock.